Journal article icon

Journal article

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.

Abstract:

Background

4CMenB is immunogenic in infants and toddlers. We assessed persistence of human complement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24 months and characterised the antibody response to a fifth dose administered at 4 years of age.

Methods

A phase 3, open label, multi-centre extension to a randomised controlled trial conducted in four countries (number of centres): Czech Republic (nineteen), Italy (four), Spain ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/j.vaccine.2016.11.009

Authors


More by this author
Department:
Oxford, MSD, Paediatrics
More by this author
Department:
Oxford, MSD, Paediatrics
More by this author
Department:
All Souls College
Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
Vaccine Journal website
Publication date:
2016-11-05
Acceptance date:
2016-11-03
DOI:
ISSN:
1873-2518
Pubs id:
pubs:664223
URN:
uri:98f24bef-54ae-45ec-b655-fb404d45c648
UUID:
uuid:98f24bef-54ae-45ec-b655-fb404d45c648
Local pid:
pubs:664223

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP